AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$ARQT

Welgus Howard G. sold $114K of ARQT

Welgus Howard G. sold 4,730 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $24.18 ($0.11M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Sep 17, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The sale adds marginal selling pressure; investors may monitor future insider activity for signals.

02

Market read

Small insider sale with limited trading relevance; primarily informational.

03

What to watch

Potential upcoming clinical trial milestones that may affect insider sentiment.

Relevance 3/10Novelty 4/10Timing: post‑market 2026-09-15

Background

Form 4 filings disclose insider transactions; a director's sale under a pre‑arranged 10b5‑1 plan is a standard disclosure.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

Director Welgus Howard G. sold 4,730 shares of ARQT for $114,371 on 2026-09-15 via a 10b5‑1 plan.

Expected impact

Limited short‑term downside risk; unlikely to move price materially.

Evidence & confidence

A $114k sale by a director represents a minor ownership change; market typically discounts such small insider sales.

Market effects

Sector

Minimal impact on biotech sector; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the director is reducing exposure, it could signal concerns about upcoming data, but the size is too small to infer.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies, ticker ARQT.

  • Individual
    Welgus Howard G.

    Director of ARQT who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

OCT 20
$ARQTHigh

Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb

Arcutis Biotherapeutics (ARQT) shares rose 10.65% to $31.89 after upgrades from Guggenheim and Cantor Fitzgerald, with price targets raised to $44 and $48 respectively. The company reported Q2 net income of $15M, up from a loss last year, driven by its eczema and psoriasis treatment Zoryve. ARQT raised its 2026 sales guidance to $525M-$540M. Institutional investors increased their holdings in Q2.

insidermonkey.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and steroid use at dermatology conferences. Phase 2 data showed 34.4% of infants with atopic dermatitis achieved clear or almost clear skin after 4 weeks. Phase 3 data showed 66.4% of patients with scalp psoriasis achieved clear or almost clear skin at Week 8. The company also presented research on seborrheic dermatitis and corticosteroid hesitancy. ARQT stock was up 1.32% on Thursday and is up 1.84% in premarket trading.

rttnews.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis presents data on ZORYVE cream for infant eczema

Arcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.

investing.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.

globenewswire.com2 min